North America and Europe
New technology prevents vaccine freeze damage
PATH scientists have developed a formulation method that protects critical childhood vaccines from freezing, thus solving a longstanding public health problem. To help safeguard these lifesaving vaccines, PATH placed the technology in the public domain and transferred it to three commercial vaccine producers.
- “Opportunities and challenges of developing thermostable vaccines,” published in Expert Review of Vaccines
- PATH’s Idea Factory
More than 1,500 people support global health by making a gift to PATH
Support from individuals is critical to PATH’s work, helping us turn innovative ideas into workable solutions for people in poor countries—and inspiring others to take action. In 2009, thousands of people took action for global health by making a gift to PATH, joining us online, or simply spreading the word.
Global Health Technologies Coalition launches
The Global Health Technologies Coalition brings more than 30 organizations together to advocate for the development of new health tools.
- Global Health Technologies Coalition website
- Innovation in Action: Policies to Accelerate the Development and Delivery of Global Health Tools
Vaccine partners team up against bacterial causes of diarrhea
We are working to develop vaccines against Shigella and enterotoxigenic Escherichia coli (ETEC), which together kill more than one million people each year.
- Developing New Vaccines Against Diarrheal Disease
- PATH’s Vaccine Resource Library: Shigella and ETEC
Team develops new tool to help countries address multidrug-resistant tuberculosis
PATH is working in Ukraine, Tanzania, and India to help countries and partners assess national tuberculosis (TB) programs and identify strengths and gaps related to preventing, diagnosing, and treating multidrug-resistant TB.
PATH’s US locations include our Seattle, Washington, headquarters and offices in Bethesda, Maryland, and Washington, DC. In Europe, we operate offices in Belgium, France, and Ukraine.